One-third of amenorrheic transmasculine people on testosterone ovulate.

Cell Rep Med

Amsterdam UMC, Location Vrije Universiteit Amsterdam, Department of Obstetrics and Gynaecology, Amsterdam, the Netherlands; Amsterdam UMC, Centre of Expertise on Gender Dysphoria, Amsterdam, the Netherlands; Amsterdam Reproduction and Development Research Institute, Amsterdam, the Netherlands. Electronic address:

Published: March 2024

Transmasculine people usually reach amenorrhea within 6 months of adequate testosterone treatment. It is often assumed that no ovulation occurs during amenorrhea. However, in this study, we report recent ovulatory activity in amenorrheic transmasculine people on testosterone therapy at gender-affirming oophorectomy. Histological signs of recent ovulatory activity, including the presence of ovulatory follicles, corpus luteum, and corpus albicans, are observed in 17 of 52 individuals (33%). This is not significantly correlated to the duration, testosterone serum levels, or type of testosterone used. These results suggest that amenorrhea does not equal anovulation in transmasculine people on adequate testosterone therapy, emphasizing the importance of contraception for people who engage in sexual activity that can result in pregnancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982961PMC
http://dx.doi.org/10.1016/j.xcrm.2024.101440DOI Listing

Publication Analysis

Top Keywords

transmasculine people
16
amenorrheic transmasculine
8
people testosterone
8
adequate testosterone
8
ovulatory activity
8
testosterone therapy
8
testosterone
6
people
5
one-third amenorrheic
4
transmasculine
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!